We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

New Device Treats Acute Kidney Injury from Sepsis

By HospiMedica International staff writers
Posted on 15 Apr 2024

Sepsis, commonly referred to as "blood poisoning," can occur due to any infectious agent, triggering a systemic response by the body to combat the infection. This response involves the activation of circulating white blood cells. The critical severity of sepsis stems not from the infectious agent itself, but rather from the excessive and often detrimental response of white blood cells. When this response becomes uncontrolled and prolonged, these cells start to indiscriminately attack not only the pathogens but also the body’s own tissues. Until now, the options available for effectively treating sepsis were scarce. Now, a new, commercially viable method offers fresh hope to thousands of children suffering from acute kidney injury who develop this often deadly condition.

The therapeutic device has been invented and developed at the University of Michigan (Ann Arbor, MI, USA) for use in children with acute kidney injury and sepsis or a septic condition requiring continuous kidney replacement (dialysis with the artificial kidney) therapy in the intensive care unit. The device, known as the selective cytopheretic device (SCD) or Quelimmune, addresses the primary cause of death in septic patients, which is the uncontrolled and excessive inflammatory response that leads to the white blood cells damaging the body’s own organs.


Image: The therapeutic tool can be used for children with kidney issues stemming from sepsis (Photo courtesy of 123RF)
Image: The therapeutic tool can be used for children with kidney issues stemming from sepsis (Photo courtesy of 123RF)

The SCD is connected to a pump outside the body that pumps the blood through the device. The SCD selectively traps the dysregulated white cells, uses pharmacologic manipulation to calm the white cells, and then releases them back into the bloodstream. The effectiveness of this approach was validated by pooled data from two pediatric clinical trials, leading to its FDA approval in March 2024 for treating pediatric patients with severe sepsis and multiorgan failure. Given that more children die annually from sepsis than from all pediatric cancers combined, medical professionals are hopeful that SCD will significantly improve survival rates.

"Sepsis starts as a local infection, but once it gets into the bloodstream, there's a high mortality rate even if the patient starts an antibiotic,” said H. David Humes, MD, professor of nephrology and internal medicine. “Our technology focuses not on treating the bacteria, but treating this dysregulated immunologic system that is overreacting and destroying tissues within the body. That's the breakthrough with this technology.”

Related Links:
University of Michigan 


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Pre-Op Planning Solution
Sectra 3D Trauma

Latest Critical Care News

Powerful AI Risk Assessment Tool Predicts Outcomes in Heart Failure Patients

Peptide-Based Hydrogels Repair Damaged Organs and Tissues On-The-Spot

One-Hour Endoscopic Procedure Could Eliminate Need for Insulin for Type 2 Diabetes